The Activist Investing Annual Review 2019
The eagerly anticipated report, produced in association with Schulte Roth & Zabel, is the definitive review of shareholder activism over the course of the past year and features the expert opinions of several key players, including those from Innisfree M&A, Moelis & Company, D.F. King, Georgeson, Finsbury, and Alvarez & Marsal.
Citron Exposes Elder Abuse Within Inogen’sSale Tactics Price Target $46
Last week, respected short seller Carson Block put out a insightful 27 page report detailing how Inogen management has misled the market with its wildly overstated claims on TAM. These TAM estimates originated from an obscure research firm that Muddy Waters referred to as “amateurish”. We recommend all shareholders read the Muddy Waters piece and its 27 pages of detail on how Inogen is deceiving the market.
http://d.muddywatersresearch.com/content/uploads/2019/02/MW_INGN_20190208.pdf
While the original Citron report on valuation and the recent MW report on TAM are interesting, they are nothing compared to what you will read in this presentation.
Whenever a new medical device is released (e.g., portable oxygen concentrators), the potential for abuse and fraud increases exponentially. No one will deny that portable oxygen concentrators are a great advancement for people suffering from COPD. Citron will acknowledge that Inogen was the first company to capitalize on this growing market.
However, we are now unveiling the dirty secrets that we have discovered through months of research. In this report, we will expose Inogen’s dirty reseller network, the systematic abuse of elders by Inogen and resellers, and why the stock will quickly re-rate lower to $46.
Citron 2018 / 2019 Reports
Citron Exposes Elder Abuse Within Inogen’s Sale Tactics Price Target $46
What a Difference a Month Makes $TWTR will be A-OK with AOC
RH The Most Compelling Story in Retail
Citron Publishes the Smoking Gun on Ligand Pharmaceuticals
Citron Research Backing Up the Sleigh on Facebook
Twitter has become the Harvey Weinstein of Social Media
Everything Has Changed: The Big 5 Canadian Cannabis Companies Have Achieved “Platform Status”
At What Point Is MNK Selective Disclosure Complete Fraud?
NIO short is a Tesla Déjà vu – Path to $12 Should Have Little Resistance
Wayfair Has Become a Case study in Diseconomies of Scale
Citron reverses opinion on Tesla
Long Pyxus International (NYSE:PYX) – Short-Term Price Target of $65
Namaste: Citron has exposed complete FRAUD that underpins the ‘Business’ of Namaste.
Namaste A Party Not to Sell Your Shares
Our Final Word on $TLRY before $50
Cronos The Dark Side of The Cannabis Space
Wayfair: Citron is listening to the smartest guys in the room
Nvidia- The Dog that Finally Caught the Car
Tilray – Next in line in a Budding Cannabis Industry
$TWTR Just Made the Turn and Is Hitting Stride
Citron Research Explains Why AbbVie is on its way to $60.
Citron Exposes History of FRAUD Behind PolarityTE
Citron expects Netflix to dip back to $340
Fitbit: From Fad to Future
Citron Research Initiates Coverage on Snap Inc. Target Price $17
Citron Changes our Position on ROKU
Inogen Needs to Take a Breath
Citron Research is Bullish on the Most Shorted Stock in the World.
Hailiang Education- China Hustle Déjà vu
Wayfair is Growing Enemies Faster than Customers
Wait til the Senate Hears Twitter’s Hidden Secret
Shopify has a BIG Facebook Problem!
Exact Sciences Corp: We admit to being early. But the science won’t be held back.
Citron 2017 & 2016 Report Archives
2017 Reports
2016 Reports
